

## Supplementary File 1: Interview Guide

### **PART 1: Prioritisation of cardiovascular disease management in the national health strategic plans and policies, and interventions (integrated care / multicomponent interventions)**

1. Please describe your current role and what it entails.
2. To start, could you briefly give a picture of the policy landscape for cardiovascular diseases in Kenya?
3. What is the process of priority setting for non-communicable diseases in Kenya?
  - **Probe:** Planning and budgeting for NCDs and cardiovascular diseases
  - **Probe:** What influences budget allocation for CVD prevention? (barriers, facilitators, recommendations)
4. In your opinion, is cardiovascular disease prevention and management prioritised in the national health policy and strategic plan in Kenya?
  - **Probe:** What specific aspects are prioritised?
5. In your opinion, what specific interventions or strategies should be / are being prioritised to improve the prevention and management of cardiovascular diseases in Kenya?
  - **Probe:** Are these interventions targeting primary prevention, secondary prevention, or both?
  - **Probe:** What levels of the health system are they implemented at (primary, secondary, tertiary)?
6. What do you think are the barriers and facilitators to the prevention and management of cardiovascular diseases in Kenya?
  - **Probe:** What are the enablers?
  - **Probe:** What are the barriers?

## **PART 2: Health economic modelling of the impact of integrated care and multicomponent interventions on cardiovascular diseases**

1. [Provide a brief description of health economics to participant] How is economic evidence used in identifying scalable and sustainable interventions for cardiovascular disease management in Kenya?
  - **Probe:** What can be done to improve the way economic evidence is used by decision makers?
  - **Probe:** How can evidence from economic analysis be improved on the side of health economists/analysts to support use of the evidence for decision making?
  - **Probe:** Who are the key stakeholders/actors in the generation or use of health economic evidence for decision-making for cardiovascular diseases in Kenya?
2. What considerations should be made in this study for modelling the cost-effectiveness of integrated care for cardiovascular diseases in Kenya?
  - **Probe:** In light of Kenya's Universal Health Coverage targets, what equity considerations should be made when modelling the cost-effectiveness of integrated care interventions for cardiovascular diseases?
3. Do you have any final comments on what we have discussed today?